
Startup Mantra: Giving nurses wings
Pune: After spending 10 years with his earlier venture upGrad, Mayank Kumar left in October 2024 to start another company — BorderPlus — with his co-founder Ayush Mathur (who was earlier with OYO). The genesis of BorderPlus began when Mayank was in Germany and happened to visit an old age home. Lack of healthcare professionals at a foreign country triggered Ayush to set up his second startup BorderPlus that aims to meet the increasing demand for skilled nurses in Europe to begin with. (AP (PIC FOR REPRESENTATION))
'I noticed there that despite having capacity they could absorb maybe 70%-80% elderly people. The reason? They lacked staff that could care for them. This was the case in most of the old age homes there. While their population was growing old, they did not have enough young, able-bodied people to look after them. Also, about 90% of the residents were women. And besides having someone to care for them, they wanted a person who they could talk to, someone to share their day with. And, unfortunately, this was missing.'
'To address this demographic crisis – this huge shortfall of caregivers, in such homes, Germany was planning to hire thousands of Indian nurses over the next few years.'
And so, Mayank's entrepreneurial mind began to work in overdrive.
'This was something we noticed in countries around the world. They were struggling to find skilled workers, especially in healthcare, logistics, and construction. A key driver of this shortage is the aging population in many developed nations. In Japan, nearly 30% of the population is over 65. Germany isn't far behind, with 22% of its population in the same age bracket. As older populations grow and birth rates decline, the pressure on essential services, especially healthcare, is increasing sharply. At the same time, India has a large, young, and trained talent pool. But most people don't have access to the right support systems to take their skills global,' he said.
This was an opportunity knocking at the door. Mayank Kumar (HT)
Mayank set out to build a solution for this need. He met with several stakeholders across countries- hospital recruiters, healthcare administrators, and policymakers. 'What we consistently heard was that the talent gap wasn't just about skills or degrees. It was about language proficiency and real-world readiness.' Mayank understood that to serve the need in those countries he had do more than just send out blue-collar workers on the next plane to Germany.
'There's no shortage of qualified professionals in India. But without strong language training, cultural preparation, and the ability to meet local standards, most would never get access to global opportunities.' And so, he got down to fill that gap in their qualification.
'That's when we realised that if we could integrate a finishing school with language training, career support, and employer demand and layer it with technology for scale and credibility, we could build something truly transformative. A platform that doesn't just move people, but prepares them to stay, grow, and thrive in their new environments.
Getting down to work
Simply getting blue-collar workers jobs abroad was not the goal was obvious. They had to be trained like in a finishing school. They had to have fluency in the foreign language, understand their customs and culture, get assistance with various legal procedures, be able to crack the visa interviews. BorderPlus helps people build global careers, not just get jobs abroad.
Mayank said, 'Finishing school helps train participants in German language and healthcare-specific communication, prepare for cultural and professional expectations, help with documents, interviews, and visa paperwork, and connect to employers abroad.'
With his tech skills and upGrad experience, Mayank devised an AI tool that can teach nurses German in 750 to 800 hours. 'If they put in five to six hours every weekday they can learn the language in seven months to about a year. Our AI-powered training platform supports learners with personalised feedback, real-time pronunciation correction, and self-paced practice modules. It complements the finishing school experience and makes sure candidates can build fluency and confidence even outside the classroom.'
The programme fee for nurses is ₹ 2 lakh and the amount is reimbursed either through a BorderPlus scholarship or relocation support.
'Our revenue model is employer-based, meaning we only earn when a hospital or recruiter successfully hires someone we've trained,' he said.
BorderPlus charges employers ₹ 4 lakh to ₹ 12 lakh per worker placed.
Building the platform
Since both the founders come with prior entrepreneurial background, assembling a strong early team and raising capital was not their biggest challenge.
Mayank, 'What mattered more was to have clarity - a clear understanding of the problem, the systems we needed to build, and how to solve it meaningfully at scale. The real work now is focused execution, integrating training, tech, and compliance into one seamless experience for both candidates and employers. We're building for trust and long-term impact, and that takes time. We're not just trying to scale, we're trying to solve the problem in a way that actually works for everyone involved. We're still building it and there's a lot more work ahead.'
The money story
Up until now Mayank and his co-founder Ayush started with founder capital of ₹ 1 crore and a few small grants, keeping it lean and intentional. In February 2025, they raised $7 million in their first institutional round. Owl Ventures led the round, with support from investors like Binny Bansal, Ritesh Agarwal, Mithun Sacheti, Apoorva Patni, and Aakash Chaudhary. 'The funds are going into scaling our finishing school model, building AI-led tools like a language bot, expanding to new sectors, and setting up more training hubs across India and beyond.' Ayush Mathur (HT)
Each candidate contributes roughly 40%–50% margin after accounting for costs. 'The current focus is on optimising delivery while maintaining quality and compliance.' In their first batch they enrolled 150 nurses who will complete their course in October-November this year.
'Even before our batch closure we are seeing our nurses getting placed.'
The country in focus is Germany but plans are afoot to cater to Japan, the UK, Canada, Europe, GCC.
Competition
Mayank is not unduly concerned about competition because he knows that at the moment there aren't many players who provide the kind of services that they do. 'There are players who focus on either recruitment or training, but not many who do both in a structured, end-to-end way. What sets us apart is our full-stack approach. We don't just find people jobs, we train them, prepare them, and support them all the way. It's about outcomes, not just placements.'
Plans to scale
Their training hubs are in Pune and Kochi. This 'finishing school' model takes a candidate from language and soft skills to culture and documentation. It runs through both physical hubs and digital tools like AI-led language bots and modular training content. Parallelly, they are working closely with employers, hospitals and governments in their destination countries.
The big picture
According to Mayank, 'The global demand for skilled professionals, especially in healthcare, is not just large, it's also accelerating. The World Health Organization projects a global shortfall of 4.5 million nurses by 2030. Countries like Germany, Italy, Japan, and the UK are actively expanding visa routes and relaxing norms to bring in foreign talent, with India emerging as a preferred source due to the strong reputation of its nurses.
India has a growing, young workforce, but most lack access to structured global pathways. That's the gap we're solving.
'We're building structured global careers backed by training, technology, and trust. Our goal is to create 42 mobility routes across sectors, beginning with healthcare and soon expanding into other high-demand fields like logistics and construction.
'Our model is vertically integrated from language training and cultural preparation to documentation, placement, and post-arrival support. For destination countries, that means better-prepared, longer-retaining talent. For candidates, it means a smoother, more supported journey to global opportunity,' he said.
Future plans
BorderPlus has seen a 20%-30% increase in demand for nurses since its launch in January this year.
'We're setting up more hubs across Delhi NCR, the North East, and South India, and expanding quickly through a franchise model. We're also scaling in the Philippines and Brazil, and actively training 150+ nurses there right now. The goal is to train 100,000 nurses in the next few months. And we're also exploring strategic partnerships and acquisitions to grow faster in key regions.'
Mayank and Ayush have set their sights across the globe. Time will tell how this will play out for India's blue-collared workers.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Hindustan Times
an hour ago
- Hindustan Times
Housing sales decline 20% in India, 25% in MMR
Mumbai: Increasing property prices and geopolitical tensions across the world have hit housing sales in seven metropolitan cities in India, with sales dropping by 20% in the second quarter of 2025 compared to the second quarter of 2024. The Mumbai Metropolitan Region (MMR) was hit the hardest, with housing sales dropping by 25%, from 41,540 units in the second quarter of 2024 to 31,275 units in the second quarter of 2025, according to a report by real estate consulting firm, Anarock. (Hindustan Times) Approximately 96,285 houses were sold in the second quarter (April-June) of 2025 across the seven metropolitan cities – National Capital Region, MMR, Bengaluru, Pune, Hyderabad, Chennai and Kolkata, compared to 120,335 houses sold in the same period in 2024. Housing sales in the seven cities increased marginally by 3% compared to the first quarter of 2025, the report shows. Chennai, the National Capital Region (NCR), Hyderabad and Bengaluru witnessed a spike in sales by 40%, 14%, 9% and 1% respectively. But in Kolkata, Pune and the MMR, housing sales dropped by 10%, 4% and 1%, respectively. 'The second quarter of 2025 was a rollercoaster for the Indian housing market, rocked by major military actions at home and abroad. The war-like climate pushed homebuyers into wait and watch mode, compounding the impact of soaring property prices over the past two years,' Anuj Puri, chairman, Anarock Group, told Hindustan Times. 'Now, with domestic tensions easing and the Reserve Bank of India's repo rate cut injecting fresh optimism, buyer sentiment is rebounding.' Similar sentiments were shared by other real estate consultants. 'Geopolitical tensions always have an impact on Indian real estate, though the degree varies depending on the geography and Indian economic interests in those countries,' said a real estate consultant, requesting anonymity. 'This time around, with America intervening in the Iran-Israel war, people feared that a medium to large-scale conflict may lead to economic slowdown or job cuts. Hence, home hunters decided to keep their purchase decisions on hold.' In keeping with the dip in sales, new launches decelerated by 16% on a year-on-year basis, from approximately 117,165 units in the second quarter of 2024 to around 98,625 units in the second quarter of 2025. Realty hotspots MMR and NCR saw the maximum new supply, accounting for 48% of the total new supply across the seven cities. MMR witnessed a 36% yearly decline and a 8% quarterly decline in new supply. One of the top developers in the MMR, who recently launched a project in the extended Navi Mumbai area, said, 'When the Ukraine-Russia conflict broke out in February 2022, we thought it would last only a few weeks, but we have been proved wrong. But that conflict did not have as much impact on India's realty industry as the one in the Middle East, especially with America's involvement.' Puri was optimistic about an uptick in sales in forthcoming quarters. 'Despite a 20% year-on-year dip in sales across the top seven cities, a 3% uptick this quarter signals renewed momentum,' he said. 'With home loan rates softening and developers largely holding prices steady, the stage is set for a potential upswing in housing sales in the coming quarters.'


Time of India
an hour ago
- Time of India
Torrent Pharma to acquire JB Chemicals at Rs 25,689 crore valuation
Torrent Pharma will acquire a controlling stake in JB Chemicals from KKR. The deal values JB Chemicals at Rs 25,689 crore. This merger will elevate Torrent to fifth position in the Indian pharmaceutical market. KKR is expected to gain a fivefold return on its 2020 investment. The combined entity aims for significant revenue and profitability growth. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Ahmedabad-based drugmaker Torrent Pharma has agreed to buy a controlling stake in JB Chemicals from global private equity firm KKR at an equity valuation of Rs 25,689 crore ($3 billion). The deal, which will see a merger of the two entities, is among the biggest in the Indian pharmaceutical sector and brings to an end year-long negotiations. They had come close to a deal last year but couldn't agree on valuation at the the acquisition of JB Chemicals, Torrent will move up to fifth rank by market share in the $26 billion Indian pharmaceutical market ahead of Alkem and Intas Pharma. ET had on June 29 been the first to report on the merger deal was announced following a marathon meeting of Torrent Pharma's board of directors on against the stock's Friday close of Rs 1,792. Torrent will also acquire up to 2.8% equity from certain employees of JB Chemicals at the Rs 1,600 apiece. The second part of the deal will follow amerger between Torrent and JB Chemicals through a scheme of arrangement. As per the approval by the two boards, upon the merger, every shareholder holding 100 shares in JB Chemicals will get 51 shares of Torrent. KKR had been the first to seek a restart of negotiations, according to the people cited above. Even at the discounted price, it will end with a fivefold return on what it paid to acquire JB Chemicals in Pharma posted FY25 revenue of Rs 11,500 crore, of which the Indian market accounted for Rs 6,393 crore. JB Chemicals recorded total FY25 sales of Rs 3,918 crore, of which the Indian market accounted for Rs 2,269 crore, growing at 20% over the previous the last decade, Torrent has grown inorganically with a string of deals that included skincare drugs maker Curatio in 2022 and more recently a range of anti-diabetes drugs from Boehringer Ingelheim. Apress statement from Torrent Pharma said the transaction marks a significant step in its ambition to create a future-ready, diversified healthcare platform combining a deep chronic segment heritage with emerging international CDMO (contract development and manufacturing) capabilities. The deal is a strong fit for Torrent and complements its India presence, helping it move into the promising field of contract manufacturing besides allowing for market synergy, an analyst said. 'Torrent has a proven record of making deals work successfully,' the person company will get access to leading brands in the chronic segment and entry into untapped therapeutic areas such as ophthalmology. Torrent said it will derive operational synergies across multiple business functions. 'We are pleased to have on board the JB Chemicals heritage and build on the platform for the future,' said Torrent Pharma executive chairman Samir Mehta. 'Torrent's deep India presence and JB Chemicals' fast-growing India business, combined with the CDMO and international footprint offers immense potential to scale both revenue and profitability.'For KKR, this follows strong investment activity in India, where the buyout group has deployed more than $2 billion in private equity investments in the past year alone, in addition to a recent $600 million financing of Manipal Group. This also builds on KKR's strong healthcare track record, including a fivefold return in Max Healthcare in 2022 that had also marked the largest block deal by a private equity firm in India, and recent investments in healthcare, including Healthcare Global Enterprises, BMH (Baby Memorial Hospital), Healthium and Chemicals said it had built a strong foundation to deliver market-leading growth, as well as consistent improvement in profitability in the medium and long term. 'As we now enter a new chapter alongside Torrent Pharmaceuticals, we are confident that the combined strengths of our organizations will unlock greater opportunities to enhance healthcare access across our markets,' said Nikhil Chopra, chief executive officer and whole time director of JB Chemicals.


Time of India
an hour ago
- Time of India
Torrent Pharma to Acquire JB Chemicals at ₹25k cr Valuation
Ahmedabad-based drugmaker Torrent Pharma has agreed to buy a controlling stake in JB Chemicals from global private equity firm KKR at an equity valuation of ₹25,689 crore ($3 billion). The deal, which will see a merger of the two entities, is among the biggest in the Indian pharmaceutical sector and brings to an end year-long negotiations. They had come close to a deal last year but couldn't agree on valuation at the time. With the acquisition of JB Chemicals, Torrent will move up to fifth rank by market share in the $26 billion Indian pharmaceutical market ahead of Alkem and Intas Pharma. ET had on June 29 been the first to report on the merger details. The deal was announced following a marathon meeting of Torrent Pharma's board of directors on Sunday. That's against the stock's Friday close of ₹1,792. Torrent will also acquire up to 2.8% equity from certain employees of JB Chemicals at the Rs 1,600 apiece. The second part of the deal will follow a merger between Torrent and JB Chemicals through a scheme of arrangement. As per the approval by the two boards, upon the merger, every shareholder holding 100 shares in JB Chemicals will get 51 shares of Torrent. KKR had been the first to seek a restart of negotiations, according to the people cited above. Even at the discounted price, it will end with a fivefold return on what it paid to acquire JB Chemicals in 2020. Torrent Pharma posted FY25 revenue of ₹ 11,500 crore, of which the Indian market accounted for Rs 6,393 crore. JB Chemicals recorded total FY25 sales of Rs 3,918 crore, of which the Indian market accounted for Rs 2,269 crore, growing at 20% over the previous year. Over the last decade, Torrent has grown inorganically with a string of deals that included skincare drugs maker Curatio in 2022 and more recently a range of anti-diabetes drugs from Boehringer Ingelheim. A press statement from Torrent Pharma said the transaction marks a significant step in its ambition to create a future-ready, diversified healthcare platform combining a deep chronic segment heritage with emerging international CDMO (contract development and manufacturing) capabilities. The deal is a strong fit for Torrent and complements its India presence, helping it move into the promising field of contract manufacturing besides allowing for market synergy, an analyst said. 'Torrent has a proven record of making deals work successfully,' the person added. The company will get access to leading brands in the chronic segment and entry into untapped therapeutic areas such as ophthalmology. Torrent said it will derive operational synergies across multiple business functions. 'We are pleased to have on board the JB Chemicals heritage and build on the platform for the future,' said Torrent Pharma executive chairman Samir Mehta. 'Torrent's deep India presence and JB Chemicals' fast-growing India business, combined with the CDMO and international footprint offers immense potential to scale both revenue and profitability.' For KKR, this follows strong investment activity in India, where the buyout group has deployed more than $2 billion in private equity investments in the past year alone, in addition to a recent $600 million financing of Manipal Group. This also builds on KKR's strong healthcare track record, including a fivefold return in Max Healthcare in 2022 that had also marked the largest block deal by a private equity firm in India, and recent investments in healthcare, including Healthcare Global Enterprises, BMH (Baby Memorial Hospital), Healthium and Infinx. JB Chemicals said it had built a strong foundation to deliver market-leading growth, as well as consistent improvement in profitability in the medium and long term. 'As we now enter a new chapter alongside Torrent Pharmaceuticals, we are confident that the combined strengths of our organizations will unlock greater opportunities to enhance healthcare access across our markets,' said Nikhil Chopra, chief executive officer and whole time director of JB Chemicals.